Consensus Outlook: Multiple Sclerosis

Home > Pharmaceutical > Neurodegenerative Disease

Market Research Report Consensus Outlook: Multiple Sclerosis
Published by	Doctor's Guide Publishing Limited (FirstWord Pharma)
Published	September 26, 2012	Product code	251331
Price	USD 4995 PDF + Excel by E-mail Consensus Outlook Only (Single User License) USD 7495 PDF + Excel by E-mail Consensus Outlook and KOL Insight (Single User License) USD 9990 PDF + Excel by E-mail Consensus Outlook Only (Team License) USD 14985 PDF by E-mail Consensus Outlook Only (Global License) USD 14990 PDF + Excel by E-mail Consensus Outlook and KOL Insight (Team License) USD 22485 PDF by E-mail Consensus Outlook and KOL Insight (Global License)

Introduction

Introduction

Abstract

Charting the Future Multiple Sclerosis Market Landscape

Over the next five years, the global multiple sclerosis (MS) market is set to grow from $12.3 billion in 2011 to $17.3 billion in 2016. Primary drivers of this growth will be the entry of new pipeline therapies, satisfying the unmet needs of convenient administration and more efficacious therapy, and continued uptake of existing therapies.

Therapy Trends Consensus Outlook: Multiple Sclerosis analyses the global MS market players and products of today and tomorrow. Start mapping your market parameters with access to the following comprehensive resources:

An in-depth 5-year forecast report based on analyst consensus, mapping the impact of future events to predicted product performance
A detailed forecast data analysis spreadsheet model comparing critical market parameters including market size, product sales, market shares and competitive status over the period 2006 to 2016
Timely event-driven market forecast report and data analysis updates over the next 12 months

FirstWord Analysis Highlights
Research Methodology
Multiple Sclerosis Marketplace
Key Multiple Sclerosis Developers
Multiple Sclerosis Class Dynamics
Gilenya (fingolimod; Novartis Mitsubishi Tanabe) Forecast
Tysabri (natalizumab; Biogen/Elan) Forecast
Copaxone (glatiramer acetate; Teva) forecast
Avonex (interferon beta-1a; Biogen) Forecast
Betaseron (interferon beta-1b; Bayer) Forecast
Rebif (interferon beta-1a; Merck) Forecast
Extavia (interferon beta-1b; Novartis) Forecast
BG-12 (dimethyl fumarate; Biogen) Forecast
Aubagio (teriflunomide; Sanofi) Forecast
Laquinimod (Teva/Active Biotech) Forecast
Lemtrada (alemtuzumab; Genzyme/Sanofi) Forecast
Daclizumab HYP (Biogen/Abbott) Forecast
Ocrelizumab (Biogen/Roche/Biogen) Forecast
Appendix

Consensus Outlook: Multiple Sclerosis published by Doctor's Guide Publishing Limited (FirstWord Pharma) in September 26, 2012. This report price starts from US $ 4995.